ReviewEuropean radiology2024
Key learning on the promise and limitations of MRI in prostate cancer screening.
Review in European radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Comparing the effectiveness of prostate cancer screening protocols: European Association of Urology- and European Randomized Study of Screening for Prostate Cancer-based strategies.International journal of cancer · 2026Trial
- Current status and future directions of AI in prostate cancer detection on MRI: a special report from the ESUR prostate MRI working group authors.European radiology · 2026Article
- Large language models and prostate MRI reporting: a stringent testbed for safe deployment under evolving AI, health-data, and cybersecurity regulation.Abdominal radiology (New York) · 2026Review
- Integrating Artificial Intelligence into Prostate MR Imaging: Technical Foundations, Clinical Applications, and Workflow Implications.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026Review
- AI decision support for increasing prostate biopsy efficiency: a retrospective multicentre, multiscanner study.European radiology · 2026Article
- Prostate MRI quality improvement: a Roadmap from the ESUR Prostate MRI Working Group.European radiology · 2026Review
- Comprehensive biochemical insights into derivatives of PSA and glycosylation-specific changes in PSA: role in diagnosis and management of prostate cancer.Clinical proteomics · 2026Review
- Olfactory Science and Technology in Prostate Cancer Diagnosis: From Invertebrate Models to Artificial Intelligence.Life (Basel, Switzerland) · 2026Review
- Integrative analysis of urinary microRNAs for prostate cancer detection: A proof-of-concept study.Translational oncology · 2026Article
- From Spreadsheet To Prediction Tool: A Practical Artificial Intelligence Guide For Urologists.Cureus · 2026Article
- Application and prospect of artificial intelligence in diagnostic imaging of prostate cancer.NPJ digital medicine · 2026Review
- Evolution of the prostate cancer diagnostic paradigm: integrated evidence and clinical pathways from targeted biopsy to biopsy-free strategy.Frontiers in oncology · 2026Review
- A comprehensive scoring system integrating clinical and radiological variables for the detection of clinically significant prostate cancer on bi-parameter MRI: multi-center comparison with multi-parametric MRI.Abdominal radiology (New York) · 2026Article
- Development and validation of a deep learning-based model for predicting prostate cancer in patients with gray-zone PSA levels: a comparative study with clinician observations.World journal of urology · 2025Article
- Using Artificial Intelligence as a Risk Prediction Model in Patients with Equivocal Multiparametric Prostate MRI Findings.Cancers · 2025Review
- Comparison of Artificial Intelligence and Radiologists in MRI-Based Prostate Cancer Diagnosis: A Meta-Analysis of Accuracy and Effectiveness.Biomedicines · 2025Article
- Usefulness of urinary biomarker-based risk score and multiparametric MRI for clinically significant prostate cancer detection in biopsy-naïve patients.Abdominal radiology (New York) · 2025Article
- Non-invasive liver fibrosis screening on CT images using radiomics.BMC medical imaging · 2025Article
- Micro-Ultrasound in the Detection of Clinically Significant Prostate Cancer: A Comprehensive Review and Comparison with Multiparametric MRI.Tomography (Ann Arbor, Mich.) · 2025Review
- ProstaPilot: A Comparative Study of Biparametric Magnetic Resonance Imaging Versus Prostate-specific Antigen as a Screening Test for Prostate Cancer.European urology open science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MRI retains its ability to reduce the harm of prostate biopsies by decreasing biopsy rates and the detection of indolent cancers in population-based screening studies aiming to find clinically significant prostate cancers. Limitations of low positive predictive values and high reader variability in diagnostic performance require optimisations in patient selection, imaging protocols, interpretation standards, diagnostic thresholds, and biopsy methods. Improvements in diagnostic accuracy could come about through emerging technologies like risk calculators and polygenic risk scores to select men for MRI. Furthermore, artificial intelligence and workflow optimisations focused on streamlining the diagnostic pathway, quality control, and assurance measures will improve MRI variability. CLINICAL RELEVANCE STATEMENT: MRI significantly reduces harm in prostate cancer screening, lowering unnecessary biopsies and minimizing the overdiagnosis of indolent cancers. MRI maintains the effective detection of high-grade cancers, thus improving the overall benefit-to-harm ratio in population-based screenings with or without using serum prostate-specific antigen (PSA) for patient selection. KEY POINTS: • The use of MRI enables the harm reduction benefits seen in individual early cancer detection to be extended to both risk-stratified and non-stratified prostate cancer screening populations. • MRI limitations include a low positive predictive value and imperfect reader variability, which require standardising interpretations, biopsy methods, and integration into a quality diagnostic pathway. • Current evidence is based on one-time point use of MRI in screening; MRI effectiveness in multiple rounds of screening is not well-documented.
Indexed as
Identifiers
38311703What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.